Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data OnKure Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
Research and development
15.9
28.2
37.7
32.1
43.8
48.3
General and administrative
3.61
11.6
16.1
4.82
10.6
14.7
Operating expenses
19.6
39.8
53.8
36.9
54.4
63
Operating income
-19.6
-39.8
-53.8
-36.9
-54.4
-63
Other non-operating income
0.05
1.89
5.67
Pre-tax income
-19.5
-39.8
-52
-77.4
Income tax
0
0
0
0
0
0
Net income
-19.5
-39.8
-52
-35.3
-52.7
-59.5
EBITDA
-19.5
-39.8
-53.8
-36.5
-53.9
-62.5
EPS, basic
-473.94
-108.12
-104.66
-124.41
-15.28
-4.40
EPS, diluted
-473.94
-108.12
-104.66
-124.41
-15.28
-4.40
Shares, basic (weighted)
0.04
0.37
0.5
0.28
3.45
13.5
Shares, diluted (weighted)
0.04
0.37
0.5
0.28
3.45
13.5
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
53.6
125
19.9
29.9
111
59.1
Short-term investments
23
81.2
75.3
0
Other current assets
1.41
6.06
5.18
3.89
2.24
1.79
Total current assets
55
154
106
33.8
113
60.8
Property, plant and equipment
0.07
0.21
0.45
1.43
1.03
0.62
Lease right-of-use assets
1.29
0.48
0.77
0.39
Other non-current assets
0.13
0.08
0.08
0.06
0.11
0.27
Total assets
55.2
154
108
35.7
115
62.1
Accounts payable
0.91
2.02
1.89
3.42
2.97
1.43
Accrued liabilities
3.67
4.18
4.83
3.66
7.03
2.69
Total current liabilities
4.58
6.2
7.12
7.29
10.5
5.92
Lease liabilities
1.06
0.47
0.55
0
Other non-current liabilities
0.17
0.01
Total liabilities
4.62
6.81
8.21
7.75
11.1
5.93
Paid-in capital
2.84
232
237
0.21
259
270
Retained earnings
-45
-84.7
-137
-102
-155
-214
Other comprehensive income
0.03
-0.04
0.01
0
Shareholders' equity
-42.1
147
-54.4
-102
104
56.2
Total equity
-42.1
147
-54.4
-102
104
56.2
Total liabilities and equity
55.2
154
108
35.7
115
62.1
Shares outstanding
0.04
0.5
0.5
3.34
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-19.5
-39.8
-52
-35.3
-52.7
-59.5
Depreciation and amortization
0.04
0.05
0.09
0.42
0.46
0.45
Stock-based compensation
0.39
3.89
4.32
0.2
4.53
11.6
Change in payables
1.49
1.78
0.52
1.71
-5.93
-4.55
Cash from operations
-18.5
-38
-47.4
-34.5
-51.1
-51.8
Capital expenditures
-0.02
-0.2
-0.35
-0.25
-0.05
-0.05
Purchases of investments
-31.4
-102
-231
Sales and maturities of investments
7.4
8.23
44.1
242
15.9
15.9
Cash from investing
7.38
-23.4
-57.8
-0.25
15.9
-0.05
Stock issued
0.09
84.6
0.19
0.03
Share buybacks
-4.4
Cash from financing
47.3
132
0.47
53.1
116
0.16
Net change in cash
36.1
71
-105
18.3
80.9
-51.7
Free cash flow
-18.6
-38.2
-47.7
-34.8
-51.2
-51.9
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.90 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-34.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-32.7%
Net income / average total assets.
Return on invested capital (ROIC)
-875.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-45.9%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-45.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-16.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
2.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
292.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
200.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
218.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
26.7x
Current assets / current liabilities.
Quick ratio
26.6x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
26.6x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.96
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.96
Cash from operations / diluted weighted shares.
Book value per share
$3.45
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.68x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.68x
Market cap / tangible book value, when positive.
FCF yield
-40.8%
Free cash flow / market cap.
Earnings yield
-50.0%
Net income / market cap (the inverse of P/E).
Was OnKure Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $59.5M.
How much free cash flow did OnKure Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $51.8M minus capital expenditures of $46.0K left free cash flow of -$51.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.